Latham & Watkins appoints Lydia Torne as life sciences and IP partner
Charlie Blackie-Kelly | October 3, 2025 | Appointment | | Latham & Watkins, intellectual property
Appointment brings specialist healthcare IP commercialisation expertise to the firm
Latham & Watkins has appointed Lydia Torne as a partner in its Healthcare & Life Sciences Practice in London, strengthening the firm’s expertise in intellectual property (IP) and commercialisation matters.
The international law firm employs almost 500 lawyers in the UK, making it the largest US firm in the country by headcount. Its Healthcare & Life Sciences Practice advises pharmaceutical and biotech companies across all stages of the pipeline, covering commercialisation, regulatory strategy, mergers and acquisitions (M&A), IP and securities law.
“Lydia is a pivotal addition to our team at a time when demand for sophisticated life sciences representation is at an all-time high,” said Robbie McLaren, global vice chair of Latham’s Healthcare & Life Sciences Industry Group, based in London. “Transactional activity in life sciences remains robust, with an increasingly complex mix of licensing and M&A. Lydia’s deep experience and outstanding track record further strengthen our global practice.”
Torne began her career at Simmons & Simmons in 2008, becoming a partner in 2021. She specialises in IP transactions, particularly the commercialisation and monetisation of IP for life sciences companies. Her work spans licensing agreements, joint ventures and consortium arrangements. She also advises on regulatory compliance, including product classification, pharmacovigilance, and data protection issues relating to clinical trials.
“I am excited to join the firm and contribute to Latham’s renowned Healthcare & Life Sciences Practice, delivering market-leading life sciences collaborations,” said Torne commented.
Related Content
Counterfeit drugs – countering the lies
As the Falsified Medicines Directive comes into effect in February 2019, Louis Goss fact checks …
Fewer patents being filed for novel infectious diseases and AMR diagnostic technologies; US leads, UK follows
Fewer patents are being filed for point-of-care diagnostic technologies aimed at tackling infectious diseases and …
Health innovation system is broken and failing patients, new report argues
The pharmaceutical industry is incentivised to set high prices and deliver short-term returns to shareholders, …
